Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has been given a $30.00 price objective by research analysts at Roth Capital in a research note issued to investors on Thursday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Roth Capital’s price target would indicate a potential upside of 188.46% from the stock’s previous close.

Other analysts also recently issued research reports about the stock. TheStreet downgraded shares of Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a report on Wednesday. Maxim Group set a $23.00 price target on shares of Sucampo Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday. Jefferies Group LLC cut their price target on shares of Sucampo Pharmaceuticals from $13.00 to $11.00 and set a “hold” rating for the company in a report on Thursday, May 4th. Zacks Investment Research upgraded shares of Sucampo Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 4th. Finally, ValuEngine downgraded shares of Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $17.63.

Sucampo Pharmaceuticals (NASDAQ:SCMP) traded up 0.48% on Thursday, hitting $10.40. The stock had a trading volume of 469,212 shares. Sucampo Pharmaceuticals has a 12 month low of $9.30 and a 12 month high of $17.55. The stock’s market cap is $480.42 million. The firm’s 50 day moving average price is $10.58 and its 200-day moving average price is $10.73.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.22 by $0.06. The business had revenue of $59.90 million during the quarter, compared to the consensus estimate of $56.44 million. Sucampo Pharmaceuticals had a negative net margin of 61.99% and a positive return on equity of 56.58%. The business’s revenue was up 15.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.24 EPS. On average, analysts forecast that Sucampo Pharmaceuticals will post $1.02 EPS for the current year.

WARNING: This article was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/08/06/sucampo-pharmaceuticals-inc-scmp-given-a-30-00-price-target-at-roth-capital.html.

A number of hedge funds have recently bought and sold shares of SCMP. Louisiana State Employees Retirement System increased its stake in Sucampo Pharmaceuticals by 1.0% in the second quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 100 shares during the period. Arizona State Retirement System increased its stake in Sucampo Pharmaceuticals by 1.6% in the second quarter. Arizona State Retirement System now owns 13,100 shares of the biopharmaceutical company’s stock valued at $138,000 after buying an additional 200 shares during the period. Capstone Asset Management Co. increased its stake in Sucampo Pharmaceuticals by 2.1% in the second quarter. Capstone Asset Management Co. now owns 12,360 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 260 shares during the period. Texas Permanent School Fund increased its stake in Sucampo Pharmaceuticals by 2.2% in the second quarter. Texas Permanent School Fund now owns 18,319 shares of the biopharmaceutical company’s stock valued at $192,000 after buying an additional 398 shares during the period. Finally, Rhumbline Advisers increased its stake in Sucampo Pharmaceuticals by 0.9% in the second quarter. Rhumbline Advisers now owns 48,810 shares of the biopharmaceutical company’s stock valued at $513,000 after buying an additional 423 shares during the period. Hedge funds and other institutional investors own 55.82% of the company’s stock.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Analyst Recommendations for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.